The SEDASYS® System is indicated for the intravenous administration of 1% (10 mg/mL) propofol injectable emulsion for the initiation and maintenance of minimal-to-moderate sedation, as defined by the American Society of Anesthesiologists (ASA) Continuum of Depth and Sedation, in ASA physical status I and II patients ≥ 18 years old undergoing colonoscopy or esophagogastroduodenoscopy (EGD) procedures.
For complete indications, contraindications, warnings, precautions, adverse events, and additional product information, see Instructions for Use and Essential Product Information.
Redefining how you look at sedation
Computer-assisted personalized sedation (CAPS) represents a paradigm shift in sedation delivery that can help address challenges in the current healthcare environment.Learn more about this new option for delivering sedation
Innovative technology for personalized drug delivery and dosing
The SEDASYS® System delivers personalized drug titration along with safeguards against the risks of oversedation.Explore how the System works and its safety features
Effective and efficient
The clinical benefits of the System were established in a pivotal clinical study that compared the SEDASYS® System with the current standard of care (benzodiazepine/opioid) sedation. With the SEDASYS® System, patients were minimally to moderately sedated, recovered faster and in more predictable timeframes and were highly satisfied with their sedation experience. Physicians were also significantly more satisfied with the sedation delivered.Review the clinical study data